NCT00761709View on ClinicalTrials.gov

Safety and Intraocular Pressure (IOP)-Lowering Efficacy of AL-39256 in Patients With Open-Angle Glaucoma or Ocular Hypertension

PHASE2CompletedINTERVENTIONAL
Enrollment

104

Participants

Timeline

Start Date

July 31, 2009

Primary Completion Date

October 31, 2009

Study Completion Date

October 31, 2009

Conditions
Open-Angle GlaucomaOcular Hypertension
Interventions
DRUG

AL-39256 Ophthalmic Suspension, 1%

DRUG

Latanoprost Ophthalmic Solution, 0.005%

DRUG

Vehicle

Inactive ingredients used as a placebo comparator

Sponsors

Lead Sponsor

Alcon Research
All Listed Sponsors
lead

Alcon Research

INDUSTRY